UNI-EN 8:Judgement in litigation relating to alleged infringement of the patent relating to montelukast in Slovenia
Firma: KRKA, TOVARNA ZDRAVIL D.D.Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 8 | / | 2013 | | ||||||
| Date of issue: | 2013-03-01 | ||||||||||
| Short name of the issuer | |||||||||||
| KRKA | |||||||||||
| Subject | |||||||||||
| Judgement in litigation relating to alleged infringement of the patent relating to montelukast in Slovenia | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Krka, d. d., Novo mesto (hereinafter as “Krka") announces to the interested public that in the litigation for alleged infringement of patent relating to the active ingredient montelukast, Krka received the judgement of the Supreme Court of Republic of Slovenia which refused the request for revision filed by Merck Frosst Canada Limited, Purdy's Wharf Tower One, 1959 Upper Water Street, Halifax, Nova Scotia, Canada and confirmed the decision of the Appeal Court in Ljubljana dated on 10 May 2012. The litigation in Slovenia is over. Krka published the information relating to montelukast dispute in Slovenia on 13 July 2012, 23 March 2010, 23 April 2009, 5 December 2008, 13 March 2008 and 14 June 2007. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Judgement montelukast Slovenia.pdf Judgement montelukast Slovenia.pdf | Final judgement for montelukast in Slovenia | ||||||||||
| KRKA, TOVARNA ZDRAVIL D.D. | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| KRKA | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 8501 | Nove Mesto | ||||||||||||
| (post code) | (city) | ||||||||||||
| Smarjeska | 6 | ||||||||||||
| (street) | (number) | ||||||||||||
| +386 7 331 21 11 | +386 7 332 15 37 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nie dotyczy | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2013-03-01 | Jože Colarič | President of the Management and Chief Executive | |||
Cena akcji Krka
Cena akcji Krka w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Krka aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Krka.
